Please assess the completion status of the following clinical trial:

Trial Title: Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy greater than 3 months~* Histologically-proven advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ~* Documented objective radiographic or clinical disease progression on two previous lines of standard therapy~* Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1~* Can provide either a newly obtained or archival tumor tissue sample for intratumoral immune-related testing and for anti-programmed cell death (PD-1)~* Female participants of childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication~* Male participants must agree to use adequate contraception starting with the first dose through 120 days after the last dose of study medication~* Adequate organ function~Exclusion Criteria:~* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication~* Has active autoimmune disease that has required systemic treatment within the 2 years prior to the first dose of study medication~* Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication~* Known central nervous system (CNS) metastases and/or carcinomatous meningitis~* Prior anti-cancer mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study medication or not recovered from adverse events due to a previously administered agent~* Prior therapy with an anti-PD-1, anti-PD-Ligand 1 (PD-L1), or anti-PD-L2 agent, or previously participated in a Merck pembrolizumab (MK-3475) study~* Has a known additional malignancy that has progressed or required active treatment within the last 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in-situ cervical cancer, and in-situ or intra-mucosal pharyngeal cancer~* Received a live vaccine within 30 days of the first dose of study medication~* Known history of Human Immunodeficiency Virus (HIV) infection~* Known active Hepatitis B or C~* History of non-infectious pneumonitis that required steroids or current pneumonitis~* Active infection requiring systemic therapy~* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study~* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab 200 mg (Type: EXPERIMENTAL): Participants will receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).